Вестра М Д., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G. Сравнение эффектов лерканидипина и рамиприла на скорость экскреции альбумина у пациентов с артериальной гипертензией, сахарным диабетом 2 типа и микроальбуминурией: исследование DIAL (Diabete, Ipertensione, Albuminuria, Lercanidipina). Кардиоваскулярная терапия и профилактика. 2010;9(7):41-48.
1. The United States Renal Data System: URSD Annual Data Report, Bethesda, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.
2. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49: 1399-408.
3. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-100.
4. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non insulin-dependent diabetes. A 10 year follow-up study of 503 patients. Diabet Med 1988; 5: 126-34.
5. Morgensen CV. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.
6. Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-92.
7. Berl T, Hunsicker LG, Lewis JB, et al. Irbersartan Diabetic Nethropathy Trial Collaborative Study Group: Cardiovascular outcomes in the irbersartan diabetic nephropathy trial in patients with Type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542-9.
8. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment of cardiovascular disease risk in older diabetic patients with systolic hypertension. N Engl J Med 1999; 340: 677-84.
9. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84.
10. Heart Outcomes prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICROHOPE substudy. Lancet 2000; 335: 253-9.
11. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.
12. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular complication in type 2 diabetes. UKPDS 39. B M J 1998; 317: 713-20.
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibitor on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprospective effect of angiotensin receptor antagonist irbersartan in patients with nephropathy. N Engl J Med 2001; 345: 851-60.
15. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl J Med 2001. 345: 861-9.
16. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
17. Fogari R, Zoppi A, Malamani GD, et al. Long-tirm effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47-53.
18. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 1042-9.
19. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-22.
20. Ruggenenti P, Perna A, Gherardi G, et al. Chronic proteinurie nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000; 35: 1155-65.
21. Estacio RO, Jeffers BW, Hiatt WH, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
22. Chan JC, Cockram C, Nicholls M, et al. Comparison of enalapril and nifedipine in treating non insulin dependent diabetes associated with hypertension: one year analysis. BMJ 1992; 305: 981-5.
23. Bakris G, Copley J, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641-50.
24. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus. A blood pressure independent effect. Circulation 2002; 106: 672-8.
25. Lindholm L, Ihsen H, Dahlof B, et al. Cardiovascular morbility and mortality in patients with diabetes mellitus in the Losartan Intervention For End point reduction in Hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 1004-10.
26. Hansson L, Lindholm L, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbility the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1744-51
